• SLS stock is up 5.65% today, driven by heightened speculation of a potential company buyout following recent executive compensation amendments.
  • Investors are also keenly anticipating the imminent Phase 3 REGAL trial readout for its lead AML immunotherapy.
  • The company's fortified cash position of approximately $135.8 million, bolstered by recent warrant exercises, further supports the multi-day rally by providing a robust operational runway.